Acarix AB (publ) (ACARIX.ST)
SEK 0.25
(-4.05%)
SEK 0.25
(-4.05%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -77.12 Million SEK | -4.33% |
| 2022 | -76.11 Million SEK | -52.82% |
| 2021 | -50.51 Million SEK | -27.09% |
| 2020 | -40.28 Million SEK | 10.11% |
| 2019 | -44.58 Million SEK | -6.4% |
| 2018 | -41.99 Million SEK | -36.13% |
| 2017 | -29.3 Million SEK | 41.17% |
| 2016 | -26.5 Million SEK | -225.3% |
| 2015 | -15.24 Million SEK | 36.02% |
| 2014 | -23.83 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -14.83 Million SEK | 32.28% |
| 2024 Q2 | -15.85 Million SEK | -6.88% |
| 2023 Q4 | -21.9 Million SEK | -33.44% |
| 2023 FY | - SEK | -4.33% |
| 2023 Q2 | -21.73 Million SEK | -38.89% |
| 2023 Q3 | -16.41 Million SEK | 24.46% |
| 2023 Q1 | -15.64 Million SEK | 29.44% |
| 2022 Q2 | -17.63 Million SEK | -26.03% |
| 2022 FY | - SEK | -52.82% |
| 2022 Q1 | -13.99 Million SEK | 8.85% |
| 2022 Q4 | -22.17 Million SEK | -10.99% |
| 2022 Q3 | -19.97 Million SEK | -13.27% |
| 2021 FY | - SEK | -27.09% |
| 2021 Q2 | -12.24 Million SEK | -13.06% |
| 2021 Q3 | -9.85 Million SEK | 19.55% |
| 2021 Q4 | -15.35 Million SEK | -55.86% |
| 2021 Q1 | -10.83 Million SEK | -1.43% |
| 2020 Q3 | -8.04 Million SEK | 15.08% |
| 2020 FY | - SEK | 10.11% |
| 2020 Q4 | -10.67 Million SEK | -32.74% |
| 2020 Q2 | -9.47 Million SEK | 3.17% |
| 2020 Q1 | -9.78 Million SEK | -8.99% |
| 2019 Q3 | -10.26 Million SEK | 8.53% |
| 2019 Q4 | -8.97 Million SEK | 12.59% |
| 2019 FY | - SEK | -6.4% |
| 2019 Q1 | -11.79 Million SEK | -3.37% |
| 2019 Q2 | -11.22 Million SEK | 4.78% |
| 2018 Q1 | -7.34 Million SEK | 36.18% |
| 2018 FY | - SEK | -36.13% |
| 2018 Q4 | -11.4 Million SEK | 5.68% |
| 2018 Q3 | -12.09 Million SEK | -36.29% |
| 2018 Q2 | -8.87 Million SEK | -20.8% |
| 2017 Q1 | -3.93 Million SEK | 89.61% |
| 2017 Q2 | -6.74 Million SEK | -71.45% |
| 2017 Q3 | -6.99 Million SEK | -3.69% |
| 2017 FY | - SEK | 41.17% |
| 2017 Q4 | -11.51 Million SEK | -64.63% |
| 2016 Q3 | -6.99 Million SEK | -184.54% |
| 2016 Q1 | -2.29 Million SEK | -1.68% |
| 2016 FY | - SEK | -225.3% |
| 2016 Q4 | -37.85 Million SEK | -441.25% |
| 2016 Q2 | -2.45 Million SEK | -7.15% |
| 2015 Q4 | -2.25 Million SEK | 0.0% |
| 2015 FY | - SEK | 36.02% |
| 2014 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ADDvise Group AB (publ) | 411.9 Million SEK | 118.723% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 118.723% |
| Arcoma AB | 6.24 Million SEK | 1334.347% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 14.292% |
| BICO Group AB (publ) | 322.3 Million SEK | 123.929% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 216.889% |
| CellaVision AB (publ) | 207.24 Million SEK | 137.213% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | -12.742% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | -175.998% |
| C-Rad AB (publ) | 48.9 Million SEK | 257.701% |
| Duearity AB (publ) | -24.77 Million SEK | -211.239% |
| Dignitana AB (publ) | -264 Thousand SEK | -29112.879% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 12.062% |
| Getinge AB (publ) | 5.92 Billion SEK | 101.301% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | -14.679% |
| Iconovo AB (publ) | -35.33 Million SEK | -118.257% |
| Integrum AB (publ) | 8.76 Million SEK | 980.234% |
| Luxbright AB (publ) | -23.86 Million SEK | -223.136% |
| Mentice AB (publ) | 28.87 Million SEK | 367.108% |
| OssDsign AB (publ) | -122.02 Million SEK | 36.796% |
| Paxman AB (publ) | 31.22 Million SEK | 346.956% |
| Promimic AB (publ) | -3.68 Million SEK | -1993.432% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 48.758% |
| SciBase Holding AB (publ) | -51.82 Million SEK | -48.801% |
| ScandiDos AB (publ) | -13.35 Million SEK | -477.433% |
| Sectra AB (publ) | 615.06 Million SEK | 112.539% |
| Sedana Medical AB (publ) | -51.67 Million SEK | -49.247% |
| Senzime AB (publ) | -118.82 Million SEK | 35.095% |
| SpectraCure AB (publ) | -20.96 Million SEK | -267.791% |
| Stille AB | 56.04 Million SEK | 237.617% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 97.579% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 160.93% |